Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Cantor Fitzgerald maintained its overweight rating and $96.00 price target on Avidity Biosciences (NASDAQ:RNA) this week. The stock, currently trading at $29.83, has received strong support from Wall Street analysts, with an overall consensus rating of Strong Buy. InvestingPro data reveals seven analysts have recently revised their earnings expectations upward.
The research firm expressed confidence in Avidity’s leadership after meeting with the company’s team in Europe. Cantor Fitzgerald described the executives as "extremely talented" and praised their work in developing treatments for rare muscle diseases. With a strong balance sheet showing more cash than debt and a robust current ratio of 16.91, the company appears well-positioned to fund its development programs.
Avidity’s focus remains on developing therapies for several severe conditions, including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD).
The research firm highlighted Avidity not only as a "top stock pick" but also as one of the few companies in the biotechnology industry with potential to achieve significant long-term success.
Cantor Fitzgerald’s maintained price target of $96.00 represents substantial upside potential from Avidity’s current trading levels as the company continues its work on rare disease treatments.
In other recent news, Avidity Biosciences has been in the spotlight with several key developments. The company reported outcomes from its 2025 Annual Meeting of Stockholders, where three Class II directors were elected to serve until 2028, and the appointment of Deloitte & Touche LLP as the independent registered public accounting firm was ratified. H.C. Wainwright has maintained its Buy rating for Avidity Biosciences, setting a price target of $68.00, emphasizing the potential of the company’s surrogate biomarker, cDUX, to expedite the approval process for its drug candidate, del-brax. Wolfe Research initiated coverage on Avidity Biosciences with an outperform rating and a $55.00 price target, noting the company’s strategic advantage in the market for myotonic dystrophy type 1 due to its comprehensive data approach.
Furthermore, Avidity Biosciences announced positive topline Phase 1/2 FORTITUDE data for its FSHD treatment and the initiation of a global Phase 3 FORWARD study, with the FDA confirming an accelerated approval pathway for del-brax. BofA Securities raised its price target for Avidity Biosciences to $54.00, maintaining a Buy rating, following the company’s regulatory alignment with the FDA for del-brax. The Phase 3 study is designed to support a full approval package for del-brax in multiple regions, including North America and Europe. These developments are closely watched by the biopharmaceutical industry as Avidity Biosciences progresses towards potentially bringing the first approved therapy for FSHD to market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.